TaiRx Enters China, Combining Novel Drug with Immunotherapy for Clinical Trials
NQ Score
0/100
N1 Content Completeness
9
AI Summary (NQ-processed)
TaiRx announced a Phase 2A clinical trial combining its novel cancer drug CVM-1118 with Innovent's antibody Sintilimab for liver cancer in China. This partnership saves 90% of trial costs. TaiRx also plans to raise NT$400-500 million and apply for an IPO this year.